Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676588 | 0.84 | CYP2A6 (0.38) | CYP2A6HSP90AA1TLR9METAP1PARP10 | |
| SCHEMBL30748444 | 0.81 | CYP2A6 (0.35) | CYP2A6CMA1AHR | |
| SCHEMBL415637 | 0.73 | CYP2A6 (0.54) | CYP2A6METAP1PARP10TDP2PARP11 | |
| SCHEMBL354022 | 0.73 | CYP2A6 (0.54) | CYP2A6METAP1PARP10TDP2PARP11 | |
| SCHEMBL1662187 | 0.72 | CYP2A6 (0.52) | CYP2A6PARP10PARP11TDP1L3MBTL1 | |
| SCHEMBL29385577 | 0.72 | CYP2A6 (0.52) | CYP2A6PARP10PARP11TDP1L3MBTL1 | |
| Ethylene SCHEMBL5830934 | 0.71 | CYP2A6 (0.50) | CYP2A6METAP1PARP10TDP2PARP11 | |
| SCHEMBL20722582 | 0.69 | CYP2A6 (0.35) | CYP2A6PARP10TDP2PARP11CMA1 | |
| SCHEMBL2869448 | 0.68 | CYP2A6 (0.42) | CYP2A6CYP3A4 | |
| SCHEMBL22534296 | 0.68 | NMT1 (0.35) | METAP1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119410365-A | Bromine-doped carbon dot and nano micelle assembly thereof, preparation method and application | 四川大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119410365-A | Bromine-doped carbon dot and nano micelle assembly thereof, preparation method and application | 四川大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-118056821-A | Compound, organic photodetector including compound, and electronic device | 三星显示有限公司 | 2024-05-21 | — | — | CN | disclosed |
| CN-117529325-A | Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives | 纳特科药品有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-110392938-B | Polar elastomer microstructures and methods of making the same | 康宁股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-115974872-A | Aza-and-ring derivatives, pharmaceutical compositions thereof and uses thereof | 南方科技大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-111808068-B | Tetraphenyl ethylene functionalized oligopolymerization thiophene derivative, preparation method and application thereof | 南京信息工程大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-114466897-A | Resin composition, film, composite material, moving body, and material for three-dimensional modeling | 三菱化学株式会社 | 2022-05-10 | — | — | CN | disclosed |
| US-8173696-B2 | Inhibitors of cysteine proteases and methods of use thereof | BAYLOR UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | BAYLOR UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
| EP-0517876-B1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | ZENECA LTD (GB) | 1996-10-23 | — | — | EP | disclosed |
| US-5541319-A | REACTING SUBSTITUTED BENZAZEPINE ETHER WITH BORON TRIHALIDE TO FORM HYDROXY GROUP, FORMING SALT WITH BASE IF DESIRED | ZENECA LIMITED (GB) | 1996-07-30 | — | — | US | disclosed |
| US-5446039-A | Treating nervous system and brain disorder, acting as excitatory amino acid antagonist | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-08-29 | — | — | US | disclosed |
| US-5254683-A | Neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0517876-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS. | ICI PLC (GB) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSB, CTSS, CTSZ | CYP2A6 2423/4885HSP90AA1 998/4885TLR9 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.